VIVUS Reports Second Quarter and First Six Months 2013 Financial Results
MOUNTAIN VIEW, Calif., Aug. 6, 2013 (GLOBE NEWSWIRE) -- VIVUS,Inc.
(Nasdaq:VVUS) ("VIVUS"), which sells the obesity drug Qsymia^® (phentermine
and topiramate extended-release) capsules CIV in the United States, today
provided a business update and reported its financial results for the second
quarter and six months ended June 30, 2013.
*On July 22, 2013, we announced that our Board of Directors had appointed
Michael Astrue to serve as its non-executive chairman of the Board of
Directors and Anthony (Tony) Zook to serve as our chief executive officer.
Mr. Zook was also appointed to our Board of Directors on July 25, 2013.
Mr. Astrue formerly served as chief executive officer of Transkaryotic
Therapies, chairman of the Massachusetts Biotechnology Council, and
Commissioner of Social Security. Mr. Zook formerly served as executive
vice president for Global Commercial Operations for AstraZeneca and
president of MedImmune.
"It is a pleasure to join VIVUS as CEO and I look forward to working with
the VIVUS team, including the Board of Directors," stated Tony Zook, chief
executive officer of VIVUS. "We intend to move quickly on four main goals:
1) expand use of Qsymia through targeted patient and physician education;
2) find the right partner for Qsymia to expand PCP reach; 3) create a
pathway for centralized approval in Europe; and 4) eliminate expenses that
are not essential to expanding use of Qsymia. We are already making
progress on these four goals."
*On July 18, 2013, we entered into a settlement agreement with First
Manhattan Co., or the Settlement Agreement, terminating the pending proxy
contest with respect to the election of our Board of Directors at our 2013
annual meeting of stockholders, or the Annual Meeting. The Settlement
Agreement provides that the Annual Meeting be adjourned to August 14,
*On July 1, 2013, we announced initial availability of Qsymia through
approximately 8,000 Walgreens, Costco and Duane Reade retail pharmacies
nationwide. As of today, the number of retail pharmacies through which
Qsymia is available is approaching 10,000 nationwide. We intend to
continue certifying and adding to the Qsymia retail pharmacy network,
including well-known national and regional chains as well as independent
pharmacies, in the coming weeks and months.
*On June 26, 2013, the European Commission, or EC, adopted the implementing
decision granting marketing authorization for SPEDRA™ (the approved trade
name for avanafil in the European Union, or EU) for the treatment of
erectile dysfunction (ED) in the EU.
*On July 5, 2013, we entered into a License and Commercialization
Agreement, or the SPEDRA Agreement, and a Commercial Supply Agreement with
Menarini to commercialize and promote SPEDRA for the treatment of ED in
over 40 European countries, plus Australia and New Zealand. Under the
SPEDRA Agreement, we will receive an upfront payment and various approval
and sales milestones plus royalties on SPEDRA sales. Within the first
year, we expect to receive approximately €39 million, including upfront
payments totaling €16 million. Menarini will also reimburse us for
payments made to cover various obligations to MTPC during the term of the
SPEDRA Agreement. We are eligible to receive up to €79 million in
milestones and other payments over the life of the SPEDRA Agreement in
addition to royalties.
*On June 19, 2013, we announced study results showing avanafil is effective
for sexual activity within 15 minutes in men with ED. In the study,
avanafil patients achieved statistically significant improvement over
placebo, in the mean proportion of attempts that resulted in erections
sufficient for successful intercourse, as early as 10 minutes for the 200
mg dose and 12 minutes for the 100 mg dose after being taken. We intend to
file an amendment to the current STENDRA and SPEDRA labels to include
*On May 21, 2013, we closed an offering of $220.0 million in 4.5%
Convertible Senior Notes due May 1, 2020, or the Convertible Notes. In
addition, on May 29, 2013, the Initial Purchasers exercised in full their
option to purchase an additional $30.0 million aggregate principal amount
of the Convertible Notes. Total net proceeds from the Convertible Notes
were approximately $241.8 million. The Convertible Notes are senior
unsecured obligations of the Company and bear interest at a fixed rate of
4.50% per annum, payable semiannually in arrears on May 1 and November 1
of each year, beginning on November 1, 2013, unless earlier purchased or
Second Quarter Financial Results
In the second quarter of 2013, net product revenue from sales of Qsymia was
$5.5 million. For the quarter ended June 30, 2013, we reported a net loss of
$55.5 million, or $0.55 net loss per share, as compared to a net loss of $24.0
million, or $0.24 net loss per share during the second quarter of 2012. The
increased net loss in the second quarter of 2013, as compared to the second
quarter of 2012, is primarily attributable to increased selling, general and
administrative expenses related to commercialization activities for Qsymia.
Included in the net loss for the quarter ended June 30, 2013 were $2.8 million
related to the proxy contest and a total charge of $4.4 million for Qsymia
inventories on hand in excess of demand, plus a purchase commitment fee due to
the manufacturer of Qsymia.
For the second quarter of 2013, there were approximately 81,000 Qsymia
prescriptions dispensed, of which approximately 24,000 were dispensed under
the Free Trial Offer. All of these prescriptions were dispensed through the
certified mail order home delivery system. As patients switch to retail, we
anticipate that the future number of prescriptions dispensed through the mail
order system will decline and prescriptions dispensed through certified retail
pharmacies will grow and eventually surpass the number of prescriptions
currently dispensed through mail order.
First Half Financial Results
Net product revenue from sales of Qsymia in the first half of 2013 was $9.6
million. For the six months ended June 30, 2013, we reported a net loss of
$109.1 million, or $1.08 net loss per share, as compared to a net loss of
$42.8 million, or $0.45 net loss per share during the first half of 2012. The
increased net loss in the first half of 2013 is again primarily attributable
to increased selling, general and administrative expenses related to
commercialization activities for Qsymia. Included in the net loss for the six
months ended June 30, 2013 were $3.5 million related to the proxy contest and
a total charge of $10.2 million for Qsymia inventories, including a purchase
commitment fee, as explained above.
Cash, Cash Equivalents and Available-for-Sale Securities
Cash, cash equivalents and available-for-sale securities (cash) totaled $358.3
million at June 30, 2013, as compared to $214.6 million at December 31, 2012.
The increase of $143.7 million is primarily due to net cash provided by
financing activities, including the net proceeds of $48.4 million from the
Senior Secured Notes with BioPharma and $241.8 million from the Convertible
Notes, less cash used to purchase capped calls of $34.7 million and cash used
in operating activities of $110.3 million.
Note to Investors
As previously announced, VIVUS will hold a conference call and an audio
webcast to discuss the second quarter and first six months of 2013 financial
results today, August 6, 2013, beginning at 1:30PM Pacific Time.Investors can
listen to this call by dialing 1-877-359-2916 and outside the U.S.
224-357-2386. A webcast replay will be available for 30 days and can be
accessed at http://ir.vivus.com/.
Qsymia is approved in the U.S. and is indicated as an adjunct to a
reduced-calorie diet and increased physical activity for chronic weight
management in adults with an initial body mass index (BMI) of 30 kg/m2 or
greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at
least one weight-related medical condition such as high blood pressure, type 2
diabetes, or high cholesterol.
The effect of Qsymia on cardiovascular morbidity and mortality has not been
established. The safety and effectiveness of Qsymia in combination with other
products intended for weight loss, including prescription and over-the-counter
drugs, and herbal preparations, have not been established.
Important Safety Information
Qsymia^® (phentermine and topiramate extended-release) capsules CIV is
contraindicated in pregnancy; in patients with glaucoma; in hyperthyroidism;
in patients receiving treatment or within 14 days following treatment with
monoamine oxidase inhibitors (MAOIs); or in patients with hypersensitivity to
sympathomimetic amines, topiramate, or any of the inactive ingredients in
Qsymia can cause fetal harm. Females of reproductive potential should have a
negative pregnancy test before treatment and monthly thereafter and use
effective contraception consistently during Qsymia therapy. If a patient
becomes pregnant while taking Qsymia, treatment should be discontinued
immediately, and the patient should be informed of the potential hazard to the
The most commonly observed side effects in controlled clinical studies, 5% or
greater and at least 1.5 times placebo, include paraesthesia, dizziness,
dysgeusia, insomnia, constipation, and dry mouth.
SPEDRA™, the trade name for avanafil in the EU, has been approved by the EMA
for the treatment of erectile dysfunction in the EU.
STENDRA is approved by the FDA for the treatment of erectile dysfunction in
the U.S. VIVUS, through collaboration arrangements with third parties, intends
to market and sell STENDRA in the U.S. and under the trade name SPEDRA in the
EU and other territories outside the U.S. Avanafil is licensed from Mitsubishi
Tanabe Pharma Corporation (MTPC). VIVUS owns worldwide development and
commercial rights to avanafil for the treatment of sexual dysfunction, with
the exception of certain Asian-Pacific Rim countries.
VIVUS has granted an exclusive license to the Menarini Group, through its
subsidiary Berlin-Chemie AG, to commercialize and promote SPEDRA for the
treatment of erectile dysfunction in over 40 European countries plus Australia
and New Zealand. VIVUS is currently in discussions with potential partners to
commercialize STENDRA in the U.S. and its other territories throughout the
For more information about STENDRA, please visit www.Stendra.com.
Important Safety Information
STENDRA™ (avanafil) is prescribed to treat erectile dysfunction (ED).
Do not take STENDRA if you take nitrates, often prescribed for chest pain, as
this may cause a sudden, unsafe drop in blood pressure.
Discuss your general health status with your healthcare provider to ensure
that you are healthy enough to engage in sexual activity. If you experience
chest pain, nausea, or any other discomforts during sex, seek immediate
STENDRA may affect the way other medicines work. Tell your healthcare provider
if you take any of the following; medicines called HIV protease inhibitors,
such as ritonavir (Norvir®), indinavir (Crixivan®), saquinavir (Fortavase® or
Invirase®) or atazanavir (Reyataz®); some types of oral antifungal medicines,
such as ketoconazole (Nizoral®), and itraconazole (Sporanox®); or some types
of antibiotics, such as clarithromycin (Biaxin®), telithromycin (Ketek®), or
In the rare event of an erection lasting more than 4 hours, seek immediate
medical help to avoid long-term injury.
In rare instances, men taking PDE5 inhibitors (oral erectile dysfunction
medicines, including STENDRA) reported a sudden decrease or loss of vision. It
is not possible to determine whether these events are related directly to
these medicines or to other factors. If you experience sudden decrease or loss
of vision, stop taking PDE5 inhibitors, including STENDRA, and call a doctor
Sudden decrease or loss of hearing has been rarely reported in people taking
PDE5 inhibitors, including STENDRA. It is not possible to determine whether
these events are related directly to the PDE5 inhibitors or to other factors.
If you experience sudden decrease or loss of hearing, stop taking STENDRA and
contact a doctor right away. If you have prostate problems or high blood
pressure for which you take medicines called alpha blockers or other
anti-hypertensives, your doctor may start you on a lower dose of STENDRA.
Drinking too much alcohol when taking STENDRA may lead to headache, dizziness,
and lower blood pressure.
STENDRA in combination with other treatments for ED is not recommended.
STENDRA does not protect against sexually transmitted diseases, including HIV.
The most common side effects of STENDRA are headache, flushing, runny nose and
Please see full patient prescribing information for STENDRA (50 mg, 100 mg,
200 mg) tablets.
VIVUS is a biopharmaceutical company commercializing and developing
innovative, next-generation therapies to address unmet needs in obesity, sleep
apnea, diabetes and sexual health. For more information about the company,
please visit www.vivus.com.
Certain statements in this press release are forward-looking within the
meaning of the Private Securities Litigation Reform Act of 1995 and are
subject to risks, uncertainties and other factors, including risks and
uncertainties related to our ability to continue to certify and add to the
Qsymia retail pharmacy network and sell Qsymia through this network; risks and
uncertainties related to the milestones, payments and royalties under the
SPEDRA Agreement; risks and uncertainties related to filing an amendment to
the current STENDRA and SPEDRA labels to include recent study results; risks
and uncertainties related to the number of prescriptions dispensed through the
mail order system and through certified retail pharmacies; risks and
uncertainties related to the completion of our STENDRA partnering discussions
on acceptable terms and on a timely basis; and risks and uncertainties related
to the launch and commercialization of SPEDRA in the EU. These risks and
uncertainties could cause actual results to differ materially from those
referred to in these forward-looking statements. The reader is cautioned not
to rely on these forward-looking statements. Investors should read the risk
factors set forth in VIVUS's Form 10-K for the year ending December 31, 2012,
as amended by the Form 10-K/A filed on April 30, 2013 and by the Form 10-K/A
filed on June 12, 2013, and periodic reports filed with the Securities and
Exchange Commission. VIVUS does not undertake an obligation to update or
revise any forward-looking statements.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)
Three Months Ended Six Months Ended
June 30 June 30 June 30 June 30
2013 2012 2013 2012
Net product revenue $5,534 $-- $9,646 $--
Cost of goods sold 572 -- 962 --
Inventory impairment and 4,448 -- 10,225 --
Research and development 9,232 8,873 16,278 15,007
Selling, general and 42,727 15,444 87,423 28,082
Total operating expenses 56,979 24,317 114,888 43,089
Loss from operations (51,445) (24,317) (105,242) (43,089)
Interest and other income (4,183) 54 (4,148) 71
Loss from continuing
operationsbefore income (55,628) (24,263) (109,390) (43,018)
Provision for income taxes (7) (3) (13) (10)
Loss from continuing (55,635) (24,266) (109,403) (43,028)
Income from discontinued 123 218 315 202
Net loss $(55,512) $(24,048) $(109,088) $(42,826)
Basic and diluted net income
(loss) per share:
Continuing operations $(0.55) $(0.24) $(1.08) $(0.45)
Discontinued operations -- -- -- --
Net loss per share $(0.55) $(0.24) $(1.08) $(0.45)
Shares used in per share
Basic and diluted 100,739 99,777 100,700 96,022
CONDENSED CONSOLIDATED BALANCE SHEETS
June 30 December 31
Cash and cash equivalents $124,713 $58,605
Available-for-sale securities 233,542 155,981
Accounts receivable, net 5,085 2,778
Inventories 34,217 25,353
Prepaid expenses and other assets 18,338 19,159
Total current assets 415,895 261,876
Property and equipment, net 3,329 1,951
Non-current assets 7,788 287
Total assets $427,012 $264,114
Accounts payable $16,777 $25,375
Accrued and other liabilities 16,047 14,680
Deferred revenue 2,846 1,150
Total current liabilities 35,670 41,205
Long term debt 206,220 --
Total liabilities 241,890 41,205
Commitments and contingencies
Common stock and additional paid-in capital 780,382 709,022
Accumulated other comprehensive income (26) 33
Accumulated deficit (595,234) (486,146)
Total stockholders' equity 185,122 222,909
Total liabilities and stockholders' equity $427,012 $264,114
*The Condensed Consolidated Balance Sheet at December 31, 2012 has been
derived from the Company's audited financial statements at that date.
CONTACT: VIVUS, Inc.
Timothy E. Morris
Chief Financial Officer
Investor Relations: The Trout Group
Press spacebar to pause and continue. Press esc to stop.